ASBP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
63.1K
+122.6%
28.4K
+565.4%
4.3K
+119.5%
1.9K
0
Cost of Revenue
50.8K
+124.8%
22.6K
+329.6%
5.3K
+397.7%
1.1K
0
Gross Profit
12.3K
+113.7%
5.8K
+675.0%
-1000
-213.1%
884
0
Operating Expenses
2.7M
+62.9%
1.7M
-10.6%
1.8M
+61.2%
1.1M
+43.3%
799.9K
R&D
233.5K
-21.3%
296.7K
+196.6%
100.0K
-51.9%
207.9K
-41.1%
352.9K
SG&A
2.2M
+61.2%
1.4M
-22.5%
1.7M
+86.3%
938.5K
+109.9%
447.0K
Operating Income
-2678222
-62.7%
-1646169
+11.0%
-1849424
-61.5%
-1145497
-43.2%
-799890
EBITDA
-2406432
-46.2%
-1646169
+11.0%
-1849424
-61.5%
-1145497
-43.2%
-799890
Net Income
-1268142
+60.7%
-3222892
+31.5%
-4707734
-154.4%
-1850493
+6.6%
-1981293
EPS (Basic)
$-1.22
+94.1%
$-20.57
$-48.00
+0.4%
$-48.19
EPS (Diluted)
$-1.22
+94.1%
$-20.57
$-48.00
+0.4%
$-48.19
Shares (Diluted)
1.0M
+562.4%
156.7K
41.3K
+0.4%
41.1K
Aspire Biopharma (ASBP) — Financials